Cargando…
Management of Atopic Dermatitis: Clinical Utility of Ruxolitinib
Atopic dermatitis (AD) is a common chronic, pruritic inflammatory skin disease that profoundly impacts patients’ quality of life. As the first FDA-approved topical JAK inhibitor, ruxolitinib 1.5% cream represents a novel therapeutic topical agent for the treatment of AD. The objective of this review...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9617518/ https://www.ncbi.nlm.nih.gov/pubmed/36316998 http://dx.doi.org/10.2147/JAA.S342051 |